Insulin aspart biosimilar (Zhuhai United Laboratories)

门冬胰岛素生物类似药（珠海联邦制药）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin aspart biosimilar (Zhuhai United Laboratories)
Drug Alias Name门冬胰岛素生物仿制药（珠海联邦制药）联邦优倍灵Ublin
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2021/07/12
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhuhai United Laboratories Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai United Laboratories Co Ltd
Inactive CompaniesZhongshan Branch of Zhuhai United Laboratories Co Ltd
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB05A10AD05
Related LinksN/A